Bryan G. Helwig

, Ph.D.


Bryan Helwig, Ph.D. is a partner with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Helwig has a wide range of experience in drafting and prosecuting patent applications in pharmaceutical, biology, biochemistry, and life sciences. In addition to U.S. prosecution Dr. Helwig is versed in prosecution of international applications. He advises on novel and emerging drug and biologic protection. Further, Dr. Helwig advises clients on freedom to operate, patent infringement, and patent validity as well as litigation and litigation-related issues.

Prior to joining MBHB, Dr. Helwig directed a research laboratory for the U.S. Department of Defense. His research portfolio was tasked with developing pharmaceutical and non-pharmaceutical therapies, as well as advancement of molecular and physiological device technologies, that aid Warfighter survival in extreme environments. The integrative research utilized a wide range of molecular biology, protein chemistry and high throughput technologies. In addition, Dr. Helwig has also served as a consultant to multiple Fortune 500 companies advising on scientific validity of labeling claims and product development.

Dr. Helwig’s graduate and post-doctoral work focused on transformation of stem cells into neuron and cardiac cells, heart failure, and alterations in central nervous control of autonomic function.

  • J.D., Chicago-Kent College of Law,

    Illinois Institute of Technology

  • ALM; M.A., Harvard University,


  • Ph.D., Kansas State University,

    Human Physiology; Doctoral Thesis: “Neuronal differentiation of stem cells derived from human umbilical cord matrix”

  • M.S., Kansas State University,

    Nutritional Biochemistry

  • B.S., Northwest Missouri State University
Bar Admissions
  • Illinois
  • U.S. Patent & Trademark Office
  • Intellectual Property Law Association of Chicago – Biotechnology Co-Chair


  • Preparing and prosecuting patent applications directed to pharmaceutical compounds and novel screening methods for multiple Fortune 500 companies.
  • Representing solo inventors in preparation and prosecution of patent applications directed to novel compounds and methods for treating disease.
  • Managing and prosecuting multiple international patent portfolios across 45 countries for a Fortune 500 pharmaceutical company.
  • Assisting in successful denial of an inter partes review petition institution decision for a global ingredient supplier
  • Conducting freedom to operate and patentability analyses for leading pharmaceutical companies

Published Articles

Dr. Helwig has authored over twenty refereed journal publications and more than twenty-five conference publications related to cardiac and systems physiology, molecular biology, stem cell biology, and heart failure.  Dr. Helwig has also published multiple trade journal and lay articles, and provided numerous media interviews. 

A.V. Gin and B. Helwig, FDA Signals Fast-Track Approval for AI-Based Medical Devices, Bloomberg Law (May 9, 2018).

Gattari, S.M. Ferguson, D. Crichton, and B. Helwig, Beyond Hybrid Licenses-Strategies for Post Patent Expiration Payments in the United States, LES Nouvelles. Mar;52(1): 31-36 (2017).

Rodriguez-Fernandez, B. Grossman, T. Yuraszeck, B.G. Helwig, L.R. Leon and F.J. Doyle III, Modeling the Intra-and Extracellular Cytokine Signaling Pathway under Heat Stroke, PLoS Comput Biol., (September 2013).

B.G. Helwig BG, T. I. Musch, R.A. Craig, M.J. Kenney,  Increased interleukin-6 receptor expression in the paraventricular nucleus of rats with heart failure., Am J Physiol Regul Integr Comp Physiol., Mar; 292(3):  R1165-73 (2007).

B.G. Helwig, S. Parimi, C.K. Ganta, R. Cober, R.J. Fels, and M.J. Kenney, Aging alters regulation of visceral sympathetic nerve responses to acute hypothermia. Am. J Physiol Regul Integr Comp Physiol., 291(3):  R573-579 (2006).

K.E. Mitchell, M.L. Weiss, B.M. Mitchell, P.Martin, D. Davis, L. Morales, B. Helwig, M. Beerenstrauch, K. Abou-Easa, T. Hildreth, D. Troyer, and S. Medicetty, Stem Cells., 21(1):50-60 (2003).